Moderator:

Daniel T. Dempsey, Philadelphia, PA

10-minute presentation, 5-minute discussion

DEVELOPMENT OF POSTOPERATIVE LOCAL TUMORS AND DISTANT METASTASES IS DIET, GENETICS, AND MICROBIOME-DEPENDENT IN A MOUSE MODEL OF COLORECTAL CANCER RECURRENCE
Ryan B. Morgan^*1, Mason Vierra¹, Meejeon Roh¹, Andrea Olivas¹, Lindsay Alpert¹, Kinga S. Olortegui¹, Colin W. Steele², Eugene B. Chang¹, Ralph Weichselbaum¹, Olga Zaborina¹, Benjamin D. Shogan^1
1The University of Chicago Medicine, Chicago, IL; ²Glasgow Royal Infirmary, Glasgow, Glasgow, United Kingdom

PROSPECTIVE STUDY OF PERIOPERATIVE CIRCULATING TUMOR DNA DYNAMICS IN PATIENTS UNDERGOING HEPATECTOMY FOR COLORECTAL LIVER METASTASES
Timothy E. Newhook^*, Michael J. Overman, Yun Shin Chun, Ching-Wei D. Tzeng, Hop Tran Cao, Yujiro Nishioka, Steven Wei, Scott Kopetz, Jean-Nicolas Vauthey
Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

CHARACTERIZING RESPONSE TO FOLFIRINOX IN PATIENT-DERIVED XENOGRAFT MODELS OF CLASSICAL AND BASAL-LIKE SUBTYPES OF PANCREATIC CANCER
Louisa Bolm^*, Birte Purschke, Natalie Petruch, Miriam Abigail A. Ricanati, Susan Kuo, Andrew L. Warshaw, Carlos Fernandez-Del Castillo, Andrew S. Liss
Department of Surgery, Massachusetts General Hospital, Boston, MA

PRE-OPERATIVE GHRELIN LEVELS MAY IMPROVE ACCURACY OF WEIGHT LOSS PREDICTION FOLLOWING ROUX-EN-Y GASTRIC BYPASS SURGERY
Mehran Karvar^*, Hassan Aliabarian, Andrei Moscalu, Cullen F. Roberts, Yingjia Chen, Eric G. Sheu, Ali Tavakkoli
Surgery, Brigham and Women's Hospital, Boston, MA

Welcome and introduction of new members, announcements of SSAT and Foundation sponsored awards, reports from the SSAT Foundation, recognition of the Foundation donors, presentation of the Public Service Award, and conferment of the Founders Medal.

INTRODUCTION
Daniel T. Dempsey, Philadelphia, PA

ADDRESS: SEVEN THINGS TO LOVE ABOUT SSAT
Jean-Nicholas Vauthey, Houston, TX

Moderator:

Jean-Nicholas Vauthey, Houston, TX

10-minute presentation, 5-minute discussion

TAILORING ADJUVANT CHEMOTHERAPY TO BIOLOGIC RESPONSES FOLLOWING NEOADJUVANT CHEMOTHERAPY IMPACTS OVERALL SURVIVAL IN PANCREATIC CANCER
Elie Ghabi^*1, Sami Shoucair¹, Ammar A. Javed², Ding Ding¹, Elizabeth Thompson¹, Lei Zheng¹, John Cameron¹, Christopher L. Wolfgang², Christopher Shubert¹, Kelly J. Lafaro¹, Richard Burkhart¹, William R. Burns¹, Jin He^1
1Johns Hopkins University School of Medicine, Baltimore, MD; ²NYU Langone Health, New York, NY

STOOL DNA-BASED SYNDECAN-2(SDC2) METHYLATION TESTING FOR THE EARLY DETECTION OF COLORECTAL CANCER IN AN AVERAGE RISK POPULATION
Suk-Hwan Lee^*1, Youn Young Park¹, Chang Woo Kim², Hyunjin Kim³, Hyoung Rae Kim⁴, Daeyoun D. Won⁵, Woojung Nam⁵, Hyung Jin Kim⁶, Bong-Hyeon Kye⁸, Sungwhan An⁷, Tae-Jeong Oh^7
1Surgery, Kyung Hee University Hospital at Gangdong, Gangdong-gu, Seoul, Korea (the Republic of); ²Ajou University School of Medicine and Graduate School of Medicine, Suwon, Gyeonggi-do, Korea (the Republic of); ³Koo Hospital, Daegu, Korea (the Republic of); ⁴Busan Hangun Hospital, Busan, Korea (the Republic of); ⁵Seoul Songdo Hospital, Seoul, Seoul, Korea (the Republic of); ⁶Catholic University of Korea Eunpyeong St Mary's Hospital, Seoul, Seoul, Korea (the Republic of); ⁷Genomictree, Daejeon, Korea (the Republic of); ⁸Catholic University of Korea Suwon St. Vincent's Hospital, Suwon, Korea (the Republic of)

INNATE IMMUNITY IN COLORECTAL LIVER METASTASES: MACROPHAGE MORPHOLOGY AND DISTRIBUTION ARE STRONG PREDICTORS OF PROGNOSIS. AN EXTERNAL VALIDATION.
Guido Costa^*1,2, Matteo Donadon^1,2, Faizan Nasir², Cristiana Soldani¹, Barbara Franceschini¹, Michela Anna Polidoro¹, Carlo Sposito^3,4, Matteo Virdis³, Di Tommaso Luca^1,2, Andrea Vingiani^3,4, Vincenzo Mazzaferro^3,4, Guido Torzilli^1,2
1IRCCS Humanitas Research Hospital, Rozzano, Lombardia, Italy; ²Humanitas University, Milan, Italy; ³Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy; ⁴Universita degli Studi di Milano, Milano, Lombardia, Italy

ORATION: ARE BULKY TUMORS IN THE POUCH OF DOUGLAS RESECTABLE WITH RECTAL SPARING? ADVANCES IN THE TREATMENT OF DESMOPLASTIC SMALL ROUND CELL TUMOR
Andrea Hayes, Washington, DC

Authors available at their posters to answer questions 12:30 PM - 1:30 PM; posters on display 9:30 AM - 4 PM.

Faculty:

Julie Hallet, Toronto, ON Heather Yeo, New York, NY

Moderators:

J. Augusto Bastidas, Los Gatos, CA Oliver S. Eng, Orange, CA Vassiliki L. Tsikitis, Portland, OR

10-minute presentation, 5-minute discussion

OSTEOPONTIN A POTENTIAL PROMOTER OF COLITIS ASSOCIATED CARCINOMA IN CHRONIC COLITIS – A MOLECULAR STUDY IN HUMANS
Maximilian Sehn^*1, Danielle Cardoso Da Silva², Manna Subhakankha², Sefer Elezkurtaj³, Michael Hummel³, Britta Siegmund², Katharina Beyer¹, Michael Schumann^2
1Department of General and Visceral Surgery, Berlin Institute of Health, Charité Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin, Berlin, Germany; ²ChariteCentrum 13 Innere Medizin mit Gastroenterologie und Nephrologie, Berlin, Berlin, Germany; ³Institute of Pathology, Berlin Institute of Health, Charité Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin, Germany, Berlin, Berlin, Germany

THERAPEUTIC EFFECT OF ORIDONIN AGAINST INFLAMMATORY BOWEL DISEASE INVOLVES INHIBITION OF INTESTINAL FIBROSIS VIA NF-?B AND P38/STAT1 PATHWAYS
Rui-Min D. Mao^*, Xiaofu Wang, Yanping Gu, Ravi Radhakrishnan
The University of Texas Medical Branch at Galveston, Galveston, TX

EXTENSIVE COLITIS AND CURRENT OR FORMER SMOKING ARE ASSOCIATED WITH POST-OPERATIVE COMPLICATIONS WITHIN 30 DAYS OF ILEAL POUCH-ANAL ANASTOMOSIS FOR ULCERATIVE COLITIS IN A STATE-LEVEL REGISTRY
Edward L. Barnes^*1, Scott Esckilsen¹, Jean Ashburn², Amy Barto³, Richard S. Bloomfeld², Ashley Cairns², Kurren Mehta³, Pooja Patel³, Jennifer Dziwis³, Reza Rahbar⁴, Timothy S. Sadiq⁴, John S. Hanson⁵, Hans Herfarth^1
1University of North Carolina School of Medicine, Chapel Hil, NC; ²Wake Forest University School of Medicine, Winston-Salem, NC; ³Duke University School of Medicine, Durham, NC; ⁴University of North Carolina System, Chapel Hill, NC; ⁵Atrium Health, Charlotte, NC

A PHASE IB/IIA STUDY OF REMESTEMCE-L, AN ALLOGENEIC BONE MARROW DERIVED MESENCHYMAL STEM CELL PRODUCT, FOR THE TREATMENT OF MEDICALLY REFRACTORY ULCERATIVE COLITIS: AN INTERIM ANALYSIS
Amy L. Lightner^*, Neda Dadgar, Clifton G. Fulmer, Justin Ream, Douglas Nachand, Scott Steele
Cleveland Clinic, Cleveland, OH

INTESTINAL MICROVASCULAR LEAK AS THE MAJOR CAUSE OF PERIOPERATIVE ILEUS
John N. Pignataro^*, Tatiana M. Midkiff, Caitlin P. Hodges, Anthony J. Bauer
Liberty University, Lynchburg, VA

PATIENT-REPORTED SOCIAL DETERMINANTS OF HEALTH NEEDS DO NOT CORRELATE WITH CENSUS TRACT MEASURES OF SOCIOECONOMIC DISADVANTAGE IN PATIENTS WITH GASTROINTESTINAL CANCERS
Scarlett Hao^*1, Ashley Wercholuk¹, Patrycja Popowicz¹, John A. Iasiello¹, Christopher W. Mejia¹, Alexander Parikh¹, Rebecca A. Snyder^1,2
1Surgery, East Carolina University Brody School of Medicine, Greenville, NC; ²ECU School of Public Health, Greenville, NC

Moderators:

Nicholas J. Zyromski, Indianapolis, IN Karen Horvath, Seattle, WA

INTRODUCTION FOR OPTIMAL MANAGEMENT OF PANCREATIC NECROSIS
William H. Nealon, Nashville, TN

EVOLVING ENDOSCOPIC APPROACHES
Martin L. Freeman, Edina, MN

TIMING AND TECHNICAL ASPECTS OF PERCUTANEOUS INTERVENTIONS
Rajesh Gupta, Chandigarh, India

THE SURGEON’S ROLE IN MANAGING PANCREATIC NECROSIS
Brendan Visser, Stanford, CA

CASE-BASED PANEL DISCUSSIONS
Nicholas J. Zyromski, Indianapolis, IN

Moderators:

Puja G. Khaitan, Washington DC Deborah S. Keller, Sacramento, CA Emily Winslow, Potomac, MD

FRAILTY: BETTER PREDICTOR OF SURGICAL OUTCOMES?
Deborah S. Keller, Sacramento, CA

WHICH SCALE TO MEASURE FRAILTY AND HOW TO APPLY IT?
Daniel I. Chu, Birmingham, AL

MANAGEMENT OF PATIENTS WITH HIGH FRAILTY SCORES: TOO SICK TO OPERATE?
Clancy J. Clark, Winston Salem, NC

ECONOMIC AND QOL CHALLENGES OF PATIENTS WITH FRAILTY
Cindy Kin, Stanford, CA

PRE-REHABILITATION TO OPTIMIZE FRAILTY AND SARCOPENIA
Amanda K. Arrington, Tucson, AZ

Q&A

Sponsored by: SSAT, ASGE, AGA

Moderators:

Wayne L. Hofstetter, Houston, TX Kenneth K. Wang, Rochester, MN

SIEWERT TYPE II GASTROESOPHAGEAL JUNCTIONAL CANCERS SHOULD BE TREATED AS GASTRIC CANCER (PRO)
Wayne L. Hofstetter, Houston, TX

SIEWERT TYPE II GASTROESOPHAGEAL JUNCTIONAL CANCERS SHOULD BE TREATED AS GASTRIC CANCER (CON)
Travis E. Grotz, Rochester, MN

SHOULD T1 ESOPHAGEAL ADENOCARCINOMA THAT HAVE UNDERGONE DEFINITIVE ENDOSCOPIC TREATMENT BE PLACED INTO SURVEILLANCE (PRO)
Kenneth K. Wang, Rochester, MN

SHOULD T1 ESOPHAGEAL ADENOCARCINOMA THAT HAVE UNDERGONE DEFINITIVE ENDOSCOPIC TREATMENT BE PLACED INTO SURVEILLANCE (CON)
Phil Ge, Houston, TX

ENDOSCOPIC MANAGEMENT OF POST ESOPHAGECTOMY LEAKS
Linda Martin, Blacksburg, VA

Q&A

Moderators:

Emily Winslow, Potomac, MD Joel E. Goldberg, Boston, MA Virginia O. Shaffer, Atlanta, GA

TEXTBOOK OUTCOME FROM THE PATIENT PERSPECTIVE
Jordan Cloyd, Columbus, OH

IS RESOLUTION OF PAIN A GOOD OUTCOME METRIC FOR CHOLECYSTECTOMY?
Carmen Latenstein, Nijmegen, Netherlands

OUTCOMES METRICS FOR ANTIREFLUX SURGERY: WHICH ARE BEST?
Amber Shada, Madison, WI

CENTERS OF EXCELLENCE AND OUTCOMES FOR RECTAL CANCER: WHERE ARE WE IN 2022?
Samuel Eisenstein, La Jolla, CA

THE CARDIOTHORACIC EXPERIENCE: DOES PUBLIC ACCESS TO SURGICAL OUTCOMES IMPROVE QUALITY?
George Tolis, Boston, MA

Q&A

Moderator: Sergio Bardaro, Cleveland, OH

SSAT LEGEND
Carlos A. Pellegrini, Seattle, WA

This session will highlight a past leader of the SSAT who was instrumental in establishing and promoting the multi-disciplinary team approach to managing complex digestive diseases. Formatted as a one-on-one interview with audience interaction, this Legends session will capture the pioneering spirit of leaders in medicine who paved a path for discovery, innovation, and improvements in care for patients with digestive disease.

Moderators:

Flavio G. Rocha, Portland, OR Heather Yeo, New York, NY

IMMEDIATE VERSUS POSTPONED INTERVENTION FOR INFECTED NECROTIZING PANCREATITIS
Rogier P. Voermans, Amsterdam, Netherlands
Discussant: Karen Horvath, Seattle, WA

Q&A

PERIOPERATIVE NIVOLUMAB MONOTHERAPY VERSUS NIVOLUMAB PLUS IPILIMUMAB IN RESECTABLE HEPATOCELLULAR CARCINOMA: A RANDOMIZED PHASE 2 TRIAL
Hop Tran Cao, Houston, TX
Discussant: Flavio G Rocha, Portland, OR

Q&A

The SSAT Foundation Reception will take place on Sunday, May 22, 2022, 6:00 - 8:00 p.m., at the Omni San Diego during the SSAT Annual Meeting at DDW 2022. All proceeds from the reception will help support the Foundation's initiatives. Plan to join us in celebrating the successes of the SSAT Foundation. Tickets are only 25 USD when purchased in advance and 40 USD if purchased at the door; advance tickets are available for purchase online.